Menu
Share this

PPD to Present at Late Phase Drug Development Conference

Deborah Covington to share insights on pregnancy registries

23 Mar. 2010

RSS

WILMINGTON, N.C. (March 23, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced Deborah Covington, Dr.P.H., global head of observational studies and pregnancy registries, will join a panel of experts at the Late Phase Drug Development World Americas conference in Princeton, N.J., to discuss the methodologies for monitoring fetal outcomes associated with drug exposure in pregnancy.

Dr. Covington will define pregnancy registries and discuss challenges, strengths and weaknesses associated with these registries. With more than 30 years of clinical research experience in epidemiology, maternal and child health, Dr. Covington provides leadership and direction to PPD's late stage research group in the conduct of registries and observational studies with a particular emphasis on global pregnancy registries.

She will be joined by Alec Walker, M.D., Dr.P.H., principal of World Health Information Science Consultants, LLC (WHISCON), and adjunct professor of epidemiology at Harvard School of Public Health. Dr. Walker is a world-renowned expert in observational studies and the safety of drugs, devices, vaccines and medical procedures. His talk will highlight the benefits and challenges associated with longitudinal record linkage studies. The presentation is Thursday, March 25, at 8 a.m. ET.

PPD and WHISCON created an alliance last year to jointly market their observational study and drug safety expertise in epidemiology and risk management services to biomedical companies, insurers and government agencies worldwide.

Late phase drug development is growing at approximately 20 percent annually because of concerns about the safety of approved drugs and the need to evaluate real world safety and effectiveness of marketed drugs.The Late Phase Drug Development World Americas conference is the first strategic forum in the United States to address major challenges in conducting strategic and compliant late stage studies.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the information presented during this presentation are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; competition within the outsourcing industry; success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.